WaveMan
WaveMan · Company
KTTA · Pasithea Therapeutics Corp.
> Search tickers & screens ⌘K
LIVE
← All companies

KTTA Pasithea Therapeutics (KTTA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001841330
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
19
13F, latest reported quarter

What the filings say about KTTA

Insiders, 180 days
+$53.0K net bought
1 buyer

Pasithea Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Pasithea Therapeutics Corp. insiders bought a net $53.0K of stock across 16 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Coastlands Capital LP
BUY
2026-06-22 SECtraded 2026-06-17
100,000
$53.0K
-29.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 2.6% of the 3,835,035 shares held after it.
  • No other insider bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Coastlands Capital LP bought about $53.0K of KTTA on Jun 17, 2026; 19 funds added in the latest 13F quarter.
STEINMAN LAWRENCE
Director
BUY
2025-12-01 SECtraded 2025-11-28
133,333
$100.0K
-66.4%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 2, 2023.
  • The trade is 66.8% of the 199,691 shares held after it.
  • 2 other insiders bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director STEINMAN LAWRENCE bought about $100.0K of KTTA on Nov 28, 2025, the largest insider purchase at the company since 2022; 2 other insiders bought within 30 days and 19 funds added in the latest 13F quarter.
Marques Tiago
Chief Executive Officer
BUY
2025-12-01 SECtraded 2025-11-28
33,333
$25.0K
-66.4%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 12, 2025.
  • The trade is 45.5% of the 73,334 shares held after it.
  • 2 other insiders bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Marques Tiago bought about $25.0K of KTTA on Nov 28, 2025, the largest insider purchase at the company since 2022; 2 other insiders bought within 30 days and 19 funds added in the latest 13F quarter.
Dumesnil Simon
Director
BUY
2025-12-01 SECtraded 2025-11-28
33,333
$25.0K
-66.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 93.0% of the 35,833 shares held after it.
  • 2 other insiders bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Dumesnil Simon bought about $25.0K of KTTA on Nov 28, 2025, the largest insider purchase at the company since 2022; 2 other insiders bought within 30 days and 19 funds added in the latest 13F quarter.
Marques Tiago
Chief Executive Officer
SELL
2025-05-14 SECtraded 2025-05-12
960
$797
-53.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 2.4% of the 40,001 shares held after it.
  • No other insider sold within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Marques Tiago sold about $797 of KTTA on May 12, 2025, the largest insider sale at the company on our record; 19 funds added in the latest 13F quarter.
16 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 11 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$53.0K over 180 days
+$53.0K of it by a 10%+ holder
more than 74% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
19 funds bought in last quarter
below 70% of Pharma & Biotech
Revenue
+3130.4% year over year
more than 98% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.8% of the float short (float per yahoo 2026-10-26) · 1.1 days to cover · settled 2026-09-30
below 80% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch KTTA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-45.2%12M
-60%-6%+48%+101%2025-102025-122026-022026-042026-062026-082026-10 2025-11-28 · STEINMAN LAWRENCE bought $100.0K2026-06-17 · Coastlands Capital LP bought $53.0K2025-11-28 · Marques Tiago bought $25.0K2025-11-28 · Dumesnil Simon bought $25.0K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns KTTA: institutional holders (13F)

13F holdings, latest reported quarter
Stonepine Capital Management, LLC
4,402,936 sh
$2.3M
Cable Car Capital, LP
3,000,000 sh
$1.5M
Jupiter Topco LLC
2,100,000 sh
$1.1M
ADAGE CAPITAL PARTNERS GP, L.L.C.
2,100,000 sh
$1.1M
Opaleye Management Inc.
2,050,000 sh
$1.1M

Congress trades in KTTA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

KTTA planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

KTTA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
AdvisorShares Psychedelics ETF
$483.2K position · as of 2026-06-30
1.1%
Fidelity Extended Market Index Fund
$55.5K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$65.1K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$9.6K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$5.7K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $53.0K bought by insiders over 180 days, 19 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

KTTA financials

Revenue growth
+3130.4%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$486.6K
four quarters, 2022-01-01 to 2022-12-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$17.0M
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-58.2%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets
-55.6%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-64.9%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-127.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/an/a$486.6K
Operating income-$20.9M-$14.2M-$16.0M-$12.6M
Net income-$20.4M-$13.9M-$16.0M-$13.9M
EPS (diluted)-2.91-12.69-0.42-1.76
Operating cash flow-$15.2M-$13.9Mn/a-$14.6M
Cash$55.2M$6.9M$16.3M$33.1M
SEC XBRL, fiscal years, as known on 2026-10-28

KTTA Stock Sonar score 5/7 axes

Find similar shapesCompare

KTTA ranks highest on growth (98th percentile) and insider conviction (65th), and lowest on institutional and government (30th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
43
Inputs
  • Return on equity-58.2% · 49 pct, sector of 545
  • Return on assets-55.6% · 41 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-64.9% · 38 pct, sector of 576
Growth
98
Inputs
  • Revenue growth, YoY+3130% · 98 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
65
Inputs
  • Net Form 4 buying (codes P and S), 180d$53K · 73 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
30
Inputs
  • Funds adding, latest quarter19 · 30 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
61
Inputs
  • Short interest, % of float+0.8% · 82 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+12.8% · 40 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

KTTA filings, in plain words

Are Pasithea Therapeutics insiders buying or selling KTTA?

In the 180 days to 2026-10-28, Pasithea Therapeutics insiders were net buyers, a net $53.0K across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Pasithea Therapeutics insiders were net buyers of KTTA, a net $53.0K across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $53.0K, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies